Olmesartan Medoxomil/Hydrochlorothiazide Msn (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil/Hydrochlorothiazide Msn, is an angiotensin II receptor blocker (ARB) presented as a combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what an ARB alone can provide.

GNH USA supplies Olmesartan Medoxomil/Hydrochlorothiazide Msn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxomil/hydrochlorothiazide is used in the management of high blood pressure by targeting the renin‑angiotensin system and promoting diuresis. - Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient. - Resistant hypertension: provides additional blood pressure reduction in patients not controlled on single‑agent therapy. - Cardiovascular risk reduction: contributes to lower risk of stroke and heart attack in hypertensive patients when combined with lifestyle measures.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Severe electrolyte imbalance - Liver function abnormalities

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy: avoid use; teratogenic risk associated with ARBs. - Concomitant drugs: review for interactions that affect potassium or renal function. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Olmesartan medoxomil/hydrochlorothiazide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - NSAIDs (high dose or chronic): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs (dual renin‑angiotensin blockade): increased risk of hypotension and kidney injury. - Lithium: may increase lithium levels, risking toxicity. - Antidiabetic agents: may require dose adjustment due to enhanced glucose lowering. - Antihistamines: may increase risk of dizziness. - Antifungal azoles: can affect drug metabolism, requiring monitoring.